viernes, 15 de junio de 2018

Vertex CF Therapies of Benefit But Too Costly Be of Good Value, Midwest CEPAC Says

Vertex CF Therapies of Benefit But Too Costly Be of Good Value, Midwest CEPAC Says

Cystic Fibrosis News Today

Orkambi, Symdeko and Kalydeco All of Benefit, But Too Costly Be of Good Value to Patients, Midwest CEPAC Says

JUNE 15, 2018

Jose Marques Lopes, PhDBY JOSE MARQUES LOPES, PHD


IN CYSTIC FIBROSIS, NEWS.
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)